Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Proteases >  Proteasome inhibitors >  MLN9708

MLN9708

Basic information Safety Supplier Related

MLN9708 Basic information

Product Name:
MLN9708
Synonyms:
  • 4-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid
  • MLN9708
  • MLN9708,MLN-9708,MLN 9708
  • 4-Carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid
  • 4-Carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid MLN9708
  • Ixazomib Citrate
  • 4-(carboxymethyl)-2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid
  • MLN 9708 - Ixazomib citrate
CAS:
1201902-80-8
MF:
C20H23BCl2N2O9
MW:
517.12
Product Categories:
  • Inhibitors
  • Inhibitor
  • Apis
Mol File:
1201902-80-8.mol
More
Less

MLN9708 Chemical Properties

Melting point:
>227°C (dec.)
Density 
1.47
storage temp. 
Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility 
DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)
pka
1.92±0.20(Predicted)
form 
Solid
color 
White to Off-White
More
Less

Safety Information

Safety Statements 
24/25
HS Code 
29329990
More
Less

MLN9708 Usage And Synthesis

Description

Ixazomib citrate is a proteasome inhibitor prodrug for the treatment of multiple myeloma in patients who have received at least one prior therapy in combination with lenalidomide and dexamethasone. The drug was developed by Takeda and reversibly inhibits the protein proteasome subunit β type-5, which is part of the 20S proteasome complex. Ixazomib citrate (XXIV) is hydrolyzed quickly in vivo to give the biologically active compound ixazomib, which presumably is the corresponding boronic acid variant of XXIV.

Uses

MLN-9708 is a novel proteasome?inhibitor.

Clinical Use

Highly selective and reversible proteasome inhibitor:
Treatment of multiple myeloma in combination with lenalidomide and dexamethasone

Synthesis

The structure of ixazomib citrate is particularly interesting in that it is one of the relatively few marketed drugs which feature a boron atom within its structure (others of note being the oncology medication bortezomib and the antifungal drug tavaborole13). The ostensible scale synthetic approach began with reaction of commercial 2,5-dichlorobenzoyl chloride (188) with glycine in aqueous NaOH to furnish amide 189 in 97% yield as a white crystalline solid. Acid 189 was then coupled with commercially available 1,3,2-benzodioxaborolane 190 in the presence of TBTU and DIPEA in DMF at low temperature to give diamide 191, which was used without purification for the next step. Borane 191 was then deprotected with (2-methylpropyl)boronic acid in methanolic HCl to provide trimer 192 in 74% as a white solid. Finally, boroxin 192 was reacted with citric acid in EtOAc to dissociate the trimer, resulting in ixazomib citrate (XXIV) in 88% yield as a crystalline solid.

MLN9708Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Alabiochem Tech.Co., Ltd.
Tel
0512-58900862 400-0707518
Email
sales@alabiochem.com
Energy Chemical
Tel
021-021-58432009 400-005-6266
Email
sales8178@energy-chemical.com
Jiangsu Vcare PharmaTech Co., Ltd.
Tel
13327700685
Email
sales@vcarepharmatech.com
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Email
sales@trio-pharmatech.com (International market)